Aclaris Therapeutics upgraded by Cantor Fitzgerald
$ACRS
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight
Get the next $ACRS alert in real time by email
Get the next $ACRS alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ACRS
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2025 | Overweight | Cantor Fitzgerald | |
| 12/23/2024 | $20.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2024 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/19/2024 | $2.00 → $7.00 | Market Perform → Outperform | Leerink Partners |
| 11/19/2024 | $8.00 | Neutral → Buy | BTIG Research |
| 11/19/2024 | $2.00 → $7.00 | Hold → Buy | Jefferies |
| 11/18/2024 | $3.00 → $13.00 | Neutral → Overweight | Piper Sandler |
| 1/22/2024 | Buy → Neutral | H.C. Wainwright |
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida.On Thursday March 27, 2025, at 9:00 AM EDT, Dr. Walker and other members of Aclaris' senior leadership team will participate in a
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
- Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases. This was published in The Journal of Pharmacology and Expe
Cantor Fitzgerald resumed coverage on Aclaris Therapeutics
Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight
Aclaris Therapeutics upgraded by H.C. Wainwright with a new price target
H.C. Wainwright upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $20.00
Aclaris Therapeutics upgraded by Cantor Fitzgerald
Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight
Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
Chief Financial Officer Balthaser Kevin converted options into 3,475 shares and covered exercise/tax liability with 727 shares, increasing direct ownership by 3% to 92,608 units (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
Chief Scientific Officer Monahan Joseph converted options into 60,925 shares and covered exercise/tax liability with 27,258 shares, increasing direct ownership by 15% to 265,662 units (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
CEO Walker Neal covered exercise/tax liability with 3,277 shares and converted options into 9,466 shares, increasing direct ownership by 0.42% to 1,466,907 units (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
SEC Form EFFECT filed by Aclaris Therapeutics Inc.
EFFECT - Aclaris Therapeutics, Inc. (0001557746) (Filer)
SEC Form S-3 filed by Aclaris Therapeutics Inc.
S-3 - Aclaris Therapeutics, Inc. (0001557746) (Filer)
SEC Form 10-K filed by Aclaris Therapeutics Inc.
10-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
Aclaris Therapeutics Announces Key Leadership Transitions
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations. "We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records," said Neal Walker, Chief Executive Officer of Aclaris. "Bob brings to Aclaris considerable experience leading investor relations programs across a number of various therapeutic sectors." Mr. Doody has nearly 20 years of biotechnology i
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
- Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
- Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an important milestone for Aclaris with the dosing of our first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis," said Dr. Neal Walker, Interim President & CEO and Chair of
SEC Form SC 13G filed by Aclaris Therapeutics Inc.
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SEC Form SC 13G filed by Aclaris Therapeutics Inc.
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SEC Form SC 13G filed by Aclaris Therapeutics Inc.
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)